Since there is no abstract we provide the first sentence
Despite the robustness of standard clinicopathologic features (tumor size and grade, nodal status, and ER/HER2 status) in clinical practice, they are inappropriate for tailoring the best treatment to individual patients with early-stage breast cancer. Even for the latest great clinical success of translational research with anti-HER2 drugs only approximately 10% of breast cancer patientsí benefits: HER2-positive disease accounts for 25% of all given and among these patients the clinical response does not exceed 40%. It is clear. Biomarkers are therefore urgently needed. Personalized treatment represents the highest priority in cancer research . Could the 76-gene signature  be used as a molecular diagnostic tool to the clinic for sparing adjuvant chemotherapy toxicity?